Atopic dermatitis (AD) is a chronic inflammatory skin condition affecting approximately 10-20% of children and 1-3% of adults, characterized by intense itching, impaired barrier function, and susceptibility to skin infections. Understanding AD requires simultaneously addressing three distinct but interconnected pathologies: genetic skin barrier defects, dysbiotic skin microbiota, and Th2-driven inflammation.
Genetic factors predisposing to atopic dermatitis primarily involve filaggrin (FLG) gene mutations. Filaggrin is a protein that polymerizes to fill keratinocyte cytoplasm, contributing to skin mechanical integrity and the scaffold for lipid deposition. Filaggrin loss-of-function mutations occur in approximately 10% of Europeans and up to 50% of people with AD, making FLG the single strongest genetic predictor of AD susceptibility. However, FLG mutations show incomplete penetrance—not all carriers develop AD—indicating that additional factors including dysbiosis and immune dysregulation contribute to disease manifestation.
The skin barrier defect in AD involves multiple components. Reduced filaggrin leads to impaired skin mechanical integrity. Additionally, AD skin shows reduced ceramides (lipid components of the skin barrier) and altered lipid composition. Antimicrobial peptides including cathelicidins and defensins are often paradoxically reduced in AD (unlike in rosacea where they're elevated), impairing antimicrobial defences. Together, these defects compromise the skin barrier's physical and chemical components, allowing increased transepidermal water loss and enhanced penetration of antigens and pathogens.
The microbiota dysbiosis in AD is dramatic and consistent. Staphylococcus aureus colonizes the skin of over 90% of AD patients versus fewer than 5% of healthy controls. S. aureus colonization correlates with disease severity—flare severity predicts S. aureus density. This dramatic dysbiosis reflects a fundamental loss of competitive exclusion: the normal skin microbiota, dominated by S. epidermidis and other commensals producing antimicrobial compounds, cannot exclude S. aureus. The reduced barrier function from filaggrin deficiency and ceramide loss allows increased resource availability, while reduced antimicrobial peptides remove a key S. aureus inhibitor.
Th2 cytokine-driven inflammation in AD creates a vicious cycle with dysbiosis. Th2 responses produce IL-4, IL-5, and IL-13, which suppress antimicrobial peptide production by keratinocytes. This further impairs barrier function and antimicrobial defences, allowing S. aureus expansion. S. aureus virulence factors including α-hemolysin directly activate mast cells and TLR2-responsive cells, amplifying Th2 responses. Additionally, S. aureus superantigens bypass normal antigen presentation mechanisms, strongly activating T cells and perpetuating Th2 responses.
The early-life gut microbiota appears to predict AD development. Longitudinal birth cohort studies show that infants who later develop AD have depleted Bifidobacterium species during the first months of life compared to infants remaining AD-free. Bifidobacteria produce propionate and acetate, short-chain fatty acids that promote regulatory T cell generation. Loss of these bacteria during critical immune development windows may fail to establish adequate Treg populations, compromising immune tolerance and allowing enhanced Th2 responses. This early-life dysbiosis precedes clinical AD manifestation by months, suggesting that intestinal dysbiosis sets up immunological predisposition toward AD development.
The immune training role of the gut microbiota extends to systemic Th2/Th1 balance. Germ-free mice have exaggerated Th2 responses and develop AD-like disease. Colonization with commensal bacteria restores Th1/Th17 responses that counter excessive Th2 predominance. Dysbiotic microbiota lacking species promoting these opposing responses fails to provide this immune counterbalance.
Treatment approaches address all three pathological domains. Barrier repair using intensive emollients restores ceramides and lipids, improving mechanical barrier function independent of immune mechanisms. Antimicrobial strategies (topical antibiotics, topical probiotics, antimicrobial silver) target S. aureus overgrowth. Topical corticosteroids and calcineurin inhibitors suppress Th2 inflammation. Dupilumab, a monoclonal antibody blocking IL-4 receptor signaling, blocks Th2 responses and demonstrates efficacy, though it increases S. aureus infection risk in some patients—confirming the critical role of immune defences in controlling dysbiotic S. aureus.
Emerging microbiota-targeted approaches use Roseomonas and other non-pathogenic bacteria to competitively exclude S. aureus. Bacteriophages targeting S. aureus show promise in animal models. Probiotic interventions targeting early-life gut dysbiosis might prevent AD development if administered during critical windows. Understanding AD's multifactorial pathogenesis has shifted therapy toward comprehensive approaches simultaneously addressing barrier function, dysbiosis, and immune dysregulation.